Pulmatrix, Inc. — 2016 Form 10-K Summary
Business context and reporting period
This annual report covers the fiscal year ended December 31, 2016. Although the request refers to 2016 Q4, the supplied filing reports annual results; it does not provide a clear standalone fourth-quarter income statement or cash-flow value.
Pulmatrix is a clinical-stage biotechnology company developing inhaled respiratory therapies using its iSPERSE dry-powder platform. It had no approved products and generated no product-sale revenue. Its principal candidates were PUR1900, an inhaled antifungal for pulmonary fungal infections; PUR0200, a COPD bronchodilator; and PUR1500, an inhaled IPF program. The 2015 comparison is not fully like-for-like: it combines Pulmatrix Operating results before the June 15, 2015 reverse merger with the combined company’s results thereafter, whereas 2016 reflects the combined entity for the full year.
Key financial metrics
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $0.835 million | $1.201 million |
| Research and development expense | $10.152 million | $7.187 million |
| General and administrative expense | $8.015 million | $17.032 million |
| Operating loss | $24.866 million | $23.018 million |
| Net loss | $27.843 million | $26.167 million |
| Net loss per share, basic and diluted | $1.88 | $3.23 |
| Cash used in operating activities | $13.243 million | $12.472 million |
Revenue was primarily collaboration reimbursement and service income, not product sales. Gross margin is not meaningfully presented for this development-stage business. At December 31, 2016, cash and cash equivalents were $4.182 million; current assets were $4.759 million and current liabilities $4.650 million. The resulting working capital was approximately $0.109 million. Accumulated deficit was $155.946 million.
The Hercules term loan had $5.954 million of principal outstanding at year-end before debt discounts and issuance costs; its carrying value was $5.803 million. The loan bears a floating rate with a 9.50% floor (10.00% at year-end), is secured by substantially all company and subsidiary assets other than intellectual property, and matures July 1, 2018. Scheduled principal payments were $2.698 million in 2017 and $3.256 million in 2018.
Changes versus the prior period
- Revenue declined $0.366 million as the Mylan-funded PUR0200 clinical study concluded.
- R&D expense rose $2.965 million, chiefly from PUR1900 development and increased employment costs.
- G&A expense fell $9.017 million, mainly because 2015 included merger-related advisory and legal expenses and higher stock compensation.
- 2016 included a $7.534 million write-off of acquired in-process R&D after the related Oculus license lapsed, plus a $5.029 million goodwill impairment. A $2.959 million tax benefit was recorded in connection with the intangible write-off.
- Despite lower G&A, net loss increased $1.676 million, reflecting the write-offs and impairment. The reported per-share loss improved as weighted-average shares increased.
- Cash declined $14.720 million during 2016, from $18.902 million to $4.182 million. Financing cash use included $1.046 million of term-loan principal payments.
Outlook, management commentary, and risks
- Management expected continued losses and rising development costs. It planned to advance PUR1900 and PUR0200 work and conduct preclinical evaluation of PUR1500. The filing gives no financial revenue or earnings guidance.
- PUR1900 clinical testing in healthy volunteers and asthma patients was expected to begin in the second half of 2017. For PUR0200, a 2016 European study identified two formulations with pharmacokinetic profiles management considered candidates for bioequivalence development; engagement with European regulators was planned for the first half of 2017.
- Mylan’s option to negotiate exclusive rights to PUR0200 outside the United States expired in 2016; Pulmatrix retained the rights and intended to seek future strategic collaborations.
- Management’s disclosures describe differing pre-financing cash-runway estimates: one states planned operations could be funded into the second quarter of 2017, while another says through the end of the third quarter. The company also stated that available funds would not fund additional clinical work. In February 2017, two registered direct offerings generated estimated net proceeds of approximately $7.5 million.
- The company reported recurring losses and negative operating cash flow, and management and the auditor stated that substantial doubt existed about its ability to continue as a going concern. The auditor’s opinion on the financial statements was unqualified, with a going-concern explanatory paragraph. Additional financing may be needed; failure to obtain it could delay, scale back, or discontinue programs.
- Other key risks include clinical and regulatory failure, dependence on contract manufacturers and CROs, single-source API purchasing for PUR0200 and PUR1900, competition, intellectual-property challenges, potential dilution, and the secured lender’s enforcement rights. No material legal proceedings were reported.
Important facts for investors to verify
- Current cash, subsequent financing proceeds, actual cash burn, and the company’s updated runway; reconcile the filing’s different runway estimates.
- Whether PUR1900 entered clinical testing on the stated schedule and the results, safety findings, and regulatory requirements for both lead programs.
- Development plans and funding for PUR0200 following expiration of Mylan’s option, including any collaboration agreements and regulatory feedback.
- The status and consequences of the lapsed Oculus license, the IPR&D write-off, remaining goodwill, and any continuing obligations or rights.
- Term-loan repayment capacity, collateral and covenant status, and potential dilution from future financings and outstanding equity awards and warrants.